COVID-19: HDL's Role in Innate Immunity and Cardiovascular Protection with COVID-19

COVID-19:HDL 在 COVID-19 的先天免疫和心血管保护中的作用

基本信息

  • 批准号:
    10153344
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

COVID19: HDL’s Role in Innate Immunity and Cardiovascular Protection with COVID-19 The novel coronavirus (SARS-CoV-2) causes a disease called COVID-19. For many people, COVID-19 has almost no symptoms, yet for others, COVID-19 is particularly dangerous and has high morbidity and mortality rates. People with pre-existing type-2 diabetes and atherosclerotic cardiovascular disease (ASCVD) have twice the risk of SARS-CoV-2 infection and are more likely to have poor outcomes. 70% of patients with ASCVD and elevated troponin die of COVID. We don’t know what intrinsic factors contribute to these disparate outcomes. High Density Lipoprotein (HDL) particles play a critical role in the innate immune system and are protective against viral and bacterial infections. HDL particles best are known for their roles protecting from atherosclerotic cardiovascular disease (ASCVD). The cardiovascular protection conferred by HDL is largely mediated by HDL’s associated proteins, which comprise about half of HDL’s mass. Mechanisms for HDL’s protection from ASCVD are shared with mechanisms for HDL’s protection from viral infections. These protective properties center around the HDL-associated proteins that mediate its anti-inflammatory and antioxidative functions. The goal of this project is to define how HDL may protect from Sars-CoV-2 infection and limit the inflammatory response to COVID-19 illness. Obesity and type-2 diabetes (DM2) lead to hypertriglyceridemia and metabolic changes that impair HDL’s anti-inflammatory and antioxidative functions. We will define if DM2 leads to HDL dysfunction and contributes to severe COVID-19 outcomes. Our overarching hypothesis is that HDL’s antiviral properties can limit SARS-CoV-2 infection and that HDL’s anti-inflammatory and antioxidative capacity limit the systemic inflammatory response to COVID-19. We have initiated a collaboration with Dr. Malall, an immunology expert running a large trial with COVID-19 patients whose de-identified samples are paired with de-identified EMR outcomes data. In AIM1 we will test the hypothesis that SARS-CoV-2 infection impairs HDL’s antioxidative and anti-inflammatory capacities, and that these changes can be predicted by proteomic signatures of HDL. We also have collaboration with Dr. Denison, an expert in coronavirus biology. In AIM2 we will test the hypothesis that HDL can reduce SARS-CoV-2 infectivity of lung epithelial cells, but that COVID-19 impairs HDL’s antiviral capacity, which can be improved with Remdesavir treatment. In AIM3 we will test the hypothesis that type-2 diabetes alters the HDL-associated protein networks that limit systemic inflammation with COVID-19 and protect against SARS-CoV-2 infection. Diabetes and cardiovascular disease are among the most prevalent problems among United States Veterans, making Veterans more likely to have poor COVID-19 outcomes. An asset to this project is that we can relate our HDL function and antiviral assays with clinical outcomes. Our studies will define proteomic signatures from HDL that are important for its antiviral effects. We ultimately aim to use HDL-directed therapies like recombinant Apo-A1 peptides to improve COVID outcomes.
COVID-19: HDL在COVID-19先天性免疫和心血管保护中的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Michael Stafford其他文献

John Michael Stafford的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Michael Stafford', 18)}}的其他基金

COVID-19: HDL's Role in Innate Immunity and Cardiovascular Protection with COVID-19
COVID-19:HDL 在 COVID-19 的先天免疫和心血管保护中的作用
  • 批准号:
    10404924
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
CETP and Sex-Differences in Metabolic and Cardiovascular Disease
CETP 与代谢和心血管疾病的性别差异
  • 批准号:
    10407032
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk
雌激素调节代谢和心血管风险的治疗潜力
  • 批准号:
    10184832
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Estrogen and coordinated carbohydrate and lipid metabolism in obesity
肥胖中的雌激素与碳水化合物和脂质代谢的协调
  • 批准号:
    9222748
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk
雌激素调节代谢和心血管风险的治疗潜力
  • 批准号:
    10899800
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk
雌激素调节代谢和心血管风险的治疗潜力
  • 批准号:
    10392424
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk
雌激素调节代谢和心血管风险的治疗潜力
  • 批准号:
    10618133
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Cholesteryl ester transfer protein, a novel mediator of insulin sensitivity
胆固醇酯转移蛋白,一种新型胰岛素敏感性介质
  • 批准号:
    8966663
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Cholesteryl ester transfer protein, a novel mediator of insulin sensitivity
胆固醇酯转移蛋白,一种新型胰岛素敏感性介质
  • 批准号:
    8633281
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Role of the CNS in the Metabolic Syndrome
中枢神经系统在代谢综合征中的作用
  • 批准号:
    7156709
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Modulation of hepatic acute phase reaction and antiviral response by pro-apaptotic substances (B13)
促凋亡物质调节肝脏急性期反应和抗病毒反应(B13)
  • 批准号:
    57771341
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
    Collaborative Research Centres
Effect of abnormal body temperature on ventilator induced lung injury and acute phase reaction
体温异常对呼吸机所致肺损伤及急性时相反应的影响
  • 批准号:
    18591710
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
gp130-dependent acute phase reaction: new therapeutical strategies to prevent vascular diseases (B 09)
gp130依赖性急性期反应:预防血管疾病的新治疗策略(B 09)
  • 批准号:
    5274832
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
    Collaborative Research Centres
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
  • 批准号:
    3477337
  • 财政年份:
    1988
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
  • 批准号:
    3477338
  • 财政年份:
    1988
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
  • 批准号:
    3477340
  • 财政年份:
    1988
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
  • 批准号:
    3477339
  • 财政年份:
    1988
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDERGIC MEDIATION OF THE ACUTE PHASE REACTION
急性期反应的神经肽能介导
  • 批准号:
    3477341
  • 财政年份:
    1988
  • 资助金额:
    --
  • 项目类别:
CENTRAL MONOAMINES IN ACUTE-PHASE REACTION
急性期反应中的中心单胺
  • 批准号:
    3405545
  • 财政年份:
    1986
  • 资助金额:
    --
  • 项目类别:
CENTRAL MONOAMINES AND OPIOIDS IN ACUTE-PHASE REACTION
急性期反应中的中心单胺和阿片类药物
  • 批准号:
    3405544
  • 财政年份:
    1986
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了